Re-MIND Alzheimer’s Clinical Trial Findings
Early-mid stage Alzheimers patient's were supplemented with omega-3 fish oils (DHA & EPA), carotenoids (lutein, zeaxanthin & meso-zeaxanthin) and vitamin E over a 12 month period.
Patient deficiencies in omega-3 fatty acids and carotenoids significantly improved Demonstrated improvements in disease progression and severity
Statistically significant improvements in working memory
Demonstrated changes in quality of life for Alzheimer's patients
Carers reported improvements in memory, mood, and day-to-day activities, such as getting dressed independently for the patients on the ReMind formulation compared to placebo.